The cost‐effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain-Reference-Cited by-同舟云学术

The cost‐effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

Published:2020-10-30 Issue:1 Volume:64 Page:66-77
ISSN:0933-7407
Container-title:Mycoses
language:en
Short-container-title:Mycoses

Author:

Azanza José Ramón¹,Grau Santiago²,Vázquez Lourdes³,Rebollo Pablo⁴^ORCID,Peral Carmen⁵,López‐Ibáñez de Aldecoa Alejandra⁵,López‐Gómez Vanessa⁶

Affiliation:

1. Clinical Pharmacology Department Clínica Universidad de Navarra Pamplona Spain

2. Pharmacy Department Hospital del Mar Universitat Autònoma de Barcelona Barcelona Spain

3. Hematology Department Hospital Clínico Universitario de Salamanca Salamanca Spain

4. Ingress‐health Oviedo Spain

5. Pharmacoeconomics Department Pfizer Madrid Spain

6. Medical Department Pfizer Madrid Spain

Funder

Pfizer

Publisher

Wiley

Subject

Infectious Diseases,Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/myc.13189

Reference46 articles.

1. Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010

2. Aspergillosis

3. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

4. Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases

5. Treatment of invasive fungal infections in high‐risk haematological patients: what have we learnt in the past 10 years?;Vallejo C;Rev Esp Quimioter,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain;Expert Review of Anti-infective Therapy;2024-03-18

2. Economic and budgetary impact evaluation of isavuconazole (Cresemba®) versus voriconazole (Vfend®) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system;PLOS ONE;2024-03-01

3. Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China;Frontiers in Public Health;2023-12-19

4. Anti-Candidal Marine Natural Products: A Review;Journal of Fungi;2023-07-28

5. Pharmacoeconomic evaluation of isavuconazole, posaconazole and voriconazole in the treatment of invasive fungal infection: initial therapy prior to pathogen differential diagnosis in China;2023-06-09